{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:19:01Z","timestamp":1769847541402,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jacl.2011.03.455","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T18:43:45Z","timestamp":1305917025000},"page":"281-287","source":"Crossref","is-referenced-by-count":11,"title":["Extended-release niacin\/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes"],"prefix":"10.1016","volume":"5","author":[{"given":"Andrew G.","family":"Bostom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra A.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darbie","family":"Maccubbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Tipping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Giezek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.03.455_bib1","unstructured":"2008 United States Renal Data System Report III. Table C.1, p.55, \u201cCounts of new end-stage renal disease patients with medical evidence forms.\u201d Available at: http:\/\/www.usrds.org\/2008\/ref\/C_Patient_Characteristics_08.pdf. Accessed May 16th, 2011."},{"key":"10.1016\/j.jacl.2011.03.455_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"Clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.03.455_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/gfi270","article-title":"Calcification and the usual suspect phosphate: Still guilty but there are other guys behind the scenes","volume":"21","author":"Ketteler","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl","key":"10.1016\/j.jacl.2011.03.455_bib4","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1681\/ASN.2006080925","article-title":"Vascular calcifications: pathogenesis, management, and impact on clinical outcomes","volume":"17","author":"Cannata-Andia","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000078700","article-title":"Impact of serum parathyroid hormone concentration and its regulatory factors on arterial stiffness in patients undergoing maintenance hemodialysis","volume":"22","author":"Suzuki","year":"2004","journal-title":"Blood Purif"},{"key":"10.1016\/j.jacl.2011.03.455_bib6","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1093\/ndt\/gfm377","article-title":"Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes","volume":"22","author":"Porter","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.03.455_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"1","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.03.455_bib8","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/j.ajkd.2005.05.025","article-title":"Relationship of phosphorus and calcium-phosphorus product with mortality in CKD","volume":"46","author":"Menon","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.03.455_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/j.ajkd.2008.06.023","article-title":"Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort","volume":"52","author":"Levin","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.03.455_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1046\/j.1523-1755.2003.00864.x","article-title":"Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia","volume":"63","author":"Amann","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.amjmed.2008.09.039","article-title":"Serum phosphorus and cardiovascular mortality in type 2 diabetes","volume":"122","author":"Chonchol","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2011.03.455_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib16","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib17","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/ndt\/gfl395","article-title":"Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders","volume":"21","author":"Galassi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.03.455_bib18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2011.03.455_bib19","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1681\/ASN.2005060663","article-title":"Control of hyperphosphatemia among patients with ESRD","volume":"16","author":"Coladonato","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.03.455_bib21","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/01.ASN.0000133022.32912.95","article-title":"Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?","volume":"15","author":"Behets","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib22","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib23","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","article-title":"Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration","volume":"67","author":"Lacour","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5414\/CNP66336","article-title":"The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease","volume":"66","author":"Pennell","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11255-008-9497-6","article-title":"Niacin and analogs for phosphate control in dialysis\u2014perspective from a developing country","volume":"41","author":"Sampathkumar","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A Randomized, double blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/089686080902900515","article-title":"The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients","volume":"29","author":"Young","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib28","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2215\/CJN.07341009","article-title":"Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial","volume":"5","author":"Maccubbin","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Abstract Supplement","key":"10.1016\/j.jacl.2011.03.455_bib29","first-page":"298","article-title":"Lipid-altering efficacy and tolerability of ER niacin\/laropiprant in type 2 diabetes mellitus patients","volume":"30","author":"MacLean","year":"2009","journal-title":"Euro Heart J"},{"key":"10.1016\/j.jacl.2011.03.455_bib30","first-page":"37","article-title":"Efficacy and safety of extended-release niacin\/laropiprant in patients with type 2 diabetes mellitus","volume":"18","author":"MacLean","year":"2011","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.jacl.2011.03.455_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1542-4758.2009.00387.x","article-title":"A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology","volume":"13","author":"Block","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.2009.246","article-title":"A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease","volume":"76","author":"Isakova","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.03.455_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2010.02.002","article-title":"Safety of extended-release niacin\/laropiprant in patients with dyslipidemia","volume":"4","author":"McKenney","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2011.03.455_bib34","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"105","article-title":"Blood calcium, phosphorus, and magnesium","author":"Portale","year":"1999"},{"key":"10.1016\/j.jacl.2011.03.455_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2011.03.455_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/0264-6021:3430705","article-title":"Regulation of intestinal Na-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3","volume":"343","author":"Katai","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.jacl.2011.03.455_bib37","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ndt\/14.5.1195","article-title":"Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine","volume":"14","author":"Katai","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.03.455_bib38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ndt\/14.3.610","article-title":"Effects of niceritrol on faecal and urinary phosphate excretion in normal rats","volume":"14","author":"Kuboyama","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.03.455_bib39","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/ndt\/gfh781","article-title":"Nicotinamide prevents the development of hyperphosphatemia by suppressing the intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure","volume":"20","author":"Eto","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.03.455_bib40","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","article-title":"Intestinal Npt2b plays a major role in phosphate absorption and homeostasis","volume":"20","author":"Sabbagh","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"issue":"12A","key":"10.1016\/j.jacl.2011.03.455_bib42","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin\u00a0(Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.03.455_bib43","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2011.03.455_bib44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.03.455_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.03.455_bib46","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","article-title":"Relation between serum phosphate level and cardiovascular event rate in people with coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.03.455_bib47","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.03.455_bib48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.03.455_bib49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2011.03.455_bib50","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.296.11.1377","article-title":"Under-representation of renal disease in randomized controlled trials of cardiovascular disease","volume":"296","author":"Coca","year":"2006","journal-title":"JAMA"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T21:08:18Z","timestamp":1637701698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411006003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1933287411006003"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.03.455","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}